# Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

> **NCT07223424** · PHASE2 · RECRUITING · sponsor: **Diwakar Davar** · enrollment: 880 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Non Small Cell Lung Cancer
- Melanoma
- Colo-rectal Cancer (dMMR/MSI-H CRC)
- Hepatocellular Carcinoma
- Ulcerative Colitis
- Esophageal Cancer
- Squamous Cell Carcinoma
- Gastric/GEJ
- Cervical Cancer
- Gastro-Esophageal Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** nivolumab
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT07223424
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2030-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223424, "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07223424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*